129 related articles for article (PubMed ID: 25572783)
21. Multiple milia formation induced by dovitinib.
Shin D; Seo J; Kim SM; Kim DY
J Dermatol; 2015 Apr; 42(4):411-3. PubMed ID: 25683141
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
[TBL] [Abstract][Full Text] [Related]
23. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
[TBL] [Abstract][Full Text] [Related]
24. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
25. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila J; Carrato A; Tabernero J; Grande E
Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
[TBL] [Abstract][Full Text] [Related]
26. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
Antoniu SA; Kolb MR
IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
[TBL] [Abstract][Full Text] [Related]
27. Dovitinib reduces prostate cancer bone metastases.
Cancer Discov; 2014 Nov; 4(11):OF3. PubMed ID: 25367965
[No Abstract] [Full Text] [Related]
28. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
29. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
Roth GJ; Heckel A; Colbatzky F; Handschuh S; Kley J; Lehmann-Lintz T; Lotz R; Tontsch-Grunt U; Walter R; Hilberg F
J Med Chem; 2009 Jul; 52(14):4466-80. PubMed ID: 19522465
[TBL] [Abstract][Full Text] [Related]
31. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
32. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.
Hasinoff BB; Wu X; Nitiss JL; Kanagasabai R; Yalowich JC
Biochem Pharmacol; 2012 Dec; 84(12):1617-26. PubMed ID: 23041231
[TBL] [Abstract][Full Text] [Related]
33. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
34. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
36. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
39. Eruptive milia and comedones during treatment with dovitinib.
Kimes K; Beasley K; Dalton SR
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437285
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib.
Hahn O; Stadler W
Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
